Skip to main content
. 2020 Jul 22;46(4):1514–1524. doi: 10.3892/ijmm.2020.4681

Figure 6.

Figure 6

miR-135b-5p agomir enhances the antitumor effects of trastuzumab in vivo. (A) The mice were treated with saline solution (control), trastuzumab, miR-135b-5p agomir or a combination of trastuzumab and miR-135b-5p agomir for 3 weeks. (B) Tumor weight in each group was detected after 3 weeks. (C) Tumor volumes of nude mice were monitored weekly. (D) Body weight of each group of nude mice was evaluated at day 27. (E) The levels of miR-135b-5p in tumor tissues was detected using reverse transcription-quantitative PCR. (F) The expression levels of cyclin D2 in tumor tissues was detected using western blotting. Relative protein expression was quantified by normalizing to β-actin levels. (G) Immunohistochemistry images and (H) quantification of proliferation in tumor tissues. Magnification ×200. *P<0.05 and **P<0.01 vs. control; ##P<0.01 vs. trastuzumab. miR, microRNA.